Alkem Laboratories collaborates with 100 hospitals in Tier-I, II cities
The initiative emphasises the importance of using controller medications for optimal asthma management
Alkem Laboratories announced 600 to 700 camps across India, collaborating with nearly 100 hospitals in Tier-I and Tier-II cities under its ‘Reliever Free India’ initiative. This nationwide initiative was launched in 2023 to revolutionise asthma management by advocating for a shift in focus from reliance on reliever medications to the importance of controller medications.
Alkem Laboratories Spokesperson said, “We’ve engaged with over 500 camps since the start of our campaign. This year, we’re expanding our commitment by organising at least 600 camps and clinics to raise awareness about asthma and its management. Our goal is to empower patients with the knowledge they need to take control of their health. Through the ‘Reliever Free India’ campaign, we’re promoting a proactive approach to asthma management, aiming to improve outcomes and enhance quality of life for individuals with this condition.”
The ‘Reliever Free India’ campaign emphasises the importance of using controller medications for optimal asthma management. While reliever medications offer immediate relief during asthma attacks, they do not address the underlying inflammation that contributes to the condition’s chronic nature. Over-reliance on relievers can lead to poor long-term outcomes and increased risk of exacerbations. Through this campaign, Alkem Laboratories seeks to educate patients, healthcare professionals, and the general public about the benefits of controller medications in preventing asthma symptoms and reducing the need for rescue medication.
